A technician works at a manufacturing facility of Chinese vaccine maker CanSino Biologics in Tianjin, China. Photo: Reuters A technician works at a manufacturing facility of Chinese vaccine maker CanSino Biologics in Tianjin, China. Photo: Reuters
A technician works at a manufacturing facility of Chinese vaccine maker CanSino Biologics in Tianjin, China. Photo: Reuters

Chinese vaccine developer CanSino targets ‘high disease burden’ nations for Covid-19 trials on health care concerns

  • The company’s phase three trial of its Ad5-nCoV vaccine candidate is being tested on some 40,000 participants in Russia, Saudi Arabia, Pakistan and Mexico
  • The last participant in the trial is expected to get the jab at the end of November, before the tests are wrapped up July 31 next year

Topic |   Coronavirus China
A technician works at a manufacturing facility of Chinese vaccine maker CanSino Biologics in Tianjin, China. Photo: Reuters A technician works at a manufacturing facility of Chinese vaccine maker CanSino Biologics in Tianjin, China. Photo: Reuters
A technician works at a manufacturing facility of Chinese vaccine maker CanSino Biologics in Tianjin, China. Photo: Reuters
READ FULL ARTICLE